4月7日, 治疗罕见肥胖症的Setmelonotide实验结果。 Rhythm Pharmaceuticals to reveal Phase 3 trial results for setmelanotide in treating rare obesity on April 7.

Rhythm制药公司将于4月7日公布3阶段试验结果, 用于治疗后天性低血压肥胖症, 这是脑损伤造成的罕见状况。 Rhythm Pharmaceuticals will announce results on April 7 from a Phase 3 trial testing setmelanotide for treating acquired hypothalamic obesity, a rare condition caused by brain damage. 试验衡量了治疗一年后病人体重指数的变化,以及饥饿和食物消费等其他因素。 The trial measured changes in patients' body mass index (BMI) after a year of treatment, along with other factors like hunger and food consumption. Setmelonotide目前被批准治疗其他形式的罕见肥胖症。 Setmelanotide is currently approved for treating other forms of rare obesity.